TLD (Tenofovir DF 300 mg + Lamivudine 300 mg + Dolutegravir 50 mg) #
Recognized as a preferred first-line antiretroviral regimen, TLD combines two nucleos(t)ide reverse transcriptase inhibitors with an integrase strand transfer inhibitor to support durable viral suppression in the treatment of HIV-1 infection, in accordance with WHO and NACO guidelines.
Product Details
Therapeutic Class
Nucleos(t)ide Reverse Transcriptase Inhibitors (Tenofovir DF + Lamivudine)
HIV Integrase Strand Transfer Inhibitor (Dolutegravir)
Indication
Treatment of HIV-1 infection in adults and adolescents as part of antiretroviral therapy (ART), in accordance with WHO and NACO recommendations.
Dosage & Administration
One tablet once daily, or as prescribed by a healthcare professional.
To be used strictly as part of an ART regimen.
Storage
Store below 30°C in a dry place, protected from light and moisture.
Disclaimer
Prescription medicine. To be used only under medical supervision and in line with WHO and NACO treatment guidelines.
*This combination is under patent protection in several markets. Supply, manufacture, or distribution is subject to applicable patent laws and local regulatory approvals.
Pack Size
30 Tablets